Nordic Nanovector Announces Betalutin® has been Granted Fast Track Designation in the US for Follicular Lymphoma

OSLO, Norway, June 12, 2018 /PRNewswire/ —
Nordic Nanovector ASA (OSE: NANO) announces that the US Food & Drug Administration (FDA) has granted Fast Track designation to Betalutin® (177Lu-lilotomab satetraxetan) for the treatment of patients with relapsed or refractory follicular…

PR NEWSWIRE

About M Fund

SITE ADMIN